{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T13:03:41Z","timestamp":1784725421200,"version":"3.55.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Peptide-activated G protein-coupled receptors (GPCRs) play crucial roles in numerous diseases, but remain difficult therapeutic targets due to the challenges in developing small-molecule drugs. Here, we explore structure-based strategies to identify small-molecule agonists of neurotensin (NTS) receptors, which hold promise for developing non-opioid analgesics. Chemical libraries of drug-like molecules are first designed based on a receptor-peptide complex, and then 14.5 million compounds are computationally docked to the orthosteric binding site of the NTS\n                    <jats:sub>1<\/jats:sub>\n                    receptor. A set of 39 top-ranked compounds is synthesized, and seven of these are experimentally confirmed to activate the NTS\n                    <jats:sub>1<\/jats:sub>\n                    receptor. Structure-guided optimization yields NTS\n                    <jats:sub>1<\/jats:sub>\n                    ligands with signaling signatures distinct from the endogenous peptide, and these compounds also exhibit high affinity for the NTS\n                    <jats:sub>2<\/jats:sub>\n                    receptor. High-resolution crystal structures of two agonists bound to the NTS\n                    <jats:sub>1<\/jats:sub>\n                    receptor confirm predicted binding modes and reveal key determinants of activation. In vivo, the compounds produce robust antinociception in rodents without inducing hypotension, consistent with a contribution of NTS\n                    <jats:sub>2<\/jats:sub>\n                    receptor activity. To facilitate broader application of our virtual screening approach to peptide-binding GPCRs, we provide access to tailored chemical libraries containing billions of readily synthesizable compounds.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-74990-1","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:35:39Z","timestamp":1784716539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Docking of virtual libraries identifies small-molecule agonists of neurotensin receptors with analgesic activity"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8782-0586","authenticated-orcid":false,"given":"Nicolas","family":"Panel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duy Duc","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7892-599X","authenticated-orcid":false,"given":"Harald","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9132-2774","authenticated-orcid":false,"given":"Mattia","family":"Deluigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6109-7123","authenticated-orcid":false,"given":"Szymon","family":"Pach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"B\u00e9lair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2259-9002","authenticated-orcid":false,"given":"Dorothee","family":"Weikert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5199-7144","authenticated-orcid":false,"given":"Christoph","family":"Klenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hilge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7951-4598","authenticated-orcid":false,"given":"Niharika","family":"Shiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Brochu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3985-2318","authenticated-orcid":false,"given":"Jean-Michel","family":"Longpr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4885-9120","authenticated-orcid":false,"given":"Frida","family":"B\u00e4llgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2121-043X","authenticated-orcid":false,"given":"Aljona","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3328-1921","authenticated-orcid":false,"given":"Jon","family":"Kapla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Kampen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6208-1091","authenticated-orcid":false,"given":"Israel","family":"Cabeza de Vaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4205-6040","authenticated-orcid":false,"given":"Jan","family":"Kihlberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6858-1460","authenticated-orcid":false,"given":"Nina","family":"Wettschureck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7627-701X","authenticated-orcid":false,"given":"Philippe","family":"Sarret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4191-5306","authenticated-orcid":false,"given":"Andreas","family":"Pl\u00fcckthun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4127-197X","authenticated-orcid":false,"given":"Peter","family":"Gmeiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4623-2977","authenticated-orcid":false,"given":"Jens","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"74990_CR1","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev-pharmtox-032112-135923","volume":"53","author":"V Katritch","year":"2013","unstructured":"Katritch, V., Cherezov, V. & Stevens, R. C. Structure-function of the G protein-coupled receptor superfamily. Annu. Rev. Pharmacol. Toxicol. 53, 531\u2013556 (2013).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"74990_CR2","first-page":"S21","volume":"176","author":"SPH Alexander","year":"2019","unstructured":"Alexander, S. P. H. et al. The concise guide to pharmacology 2019\/20: G protein-coupled receptors. Br. J. Pharmacol. 176, S21\u2013S141 (2019).","journal-title":"Br. J. Pharmacol."},{"key":"74990_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41573-025-01139-y","volume":"24","author":"JS Lorente","year":"2025","unstructured":"Lorente, J. S. et al. GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov. 24, 1\u201322 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"74990_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cell.2020.03.003","volume":"181","author":"M Congreve","year":"2020","unstructured":"Congreve, M., de Graaf, C., Swain, N. A. & Tate, C. G. Impact of GPCR Structures on Drug Discovery. Cell 181, 81\u201391 (2020).","journal-title":"Cell"},{"key":"74990_CR5","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1124\/mol.119.115915","volume":"96","author":"IG Tikhonova","year":"2019","unstructured":"Tikhonova, I. G., Gigoux, V. & Fourmy, D. Understanding peptide binding in class A G protein-coupled receptors. Mol. Pharmacol. 96, 550\u2013561 (2019).","journal-title":"Mol. Pharmacol."},{"key":"74990_CR6","doi-asserted-by":"publisher","first-page":"D335","DOI":"10.1093\/nar\/gkaa1080","volume":"49","author":"AJ Kooistra","year":"2021","unstructured":"Kooistra, A. J. et al. GPCRdb in 2021: integrating GPCR sequence, structure and function. Nucleic Acids Res. 49, D335\u2013D343 (2021).","journal-title":"Nucleic Acids Res"},{"key":"74990_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41573-020-0062-z","volume":"19","author":"AP Davenport","year":"2020","unstructured":"Davenport, A. P., Scully, C. C. G., de Graaf, C., Brown, A. J. H. & Maguire, J. J. Advances in therapeutic peptides targeting G protein-coupled receptors. Nat. Rev. Drug Discov. 19, 389\u2013413 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"74990_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-00904-4","volume":"7","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. Therapeutic peptides: current applications and future directions. Sig. Transduct. Target. Ther. 7, 1\u201327 (2022).","journal-title":"Sig. Transduct. Target. Ther."},{"key":"74990_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejphar.2013.03.004","volume":"716","author":"P Kleczkowska","year":"2013","unstructured":"Kleczkowska, P. & Lipkowski, A. W. Neurotensin and neurotensin receptors: characteristic, structure\u2013activity relationship and pain modulation\u2014A review. Eur. J. Pharmacol. 716, 54\u201360 (2013).","journal-title":"Eur. J. Pharmacol."},{"key":"74990_CR10","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1136\/jnnp.70.6.784","volume":"70","author":"RM Schimpff","year":"2001","unstructured":"Schimpff, R. M. et al. Increased plasma neurotensin concentrations in patients with Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry. 70, 784\u2013786 (2001).","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"74990_CR11","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/nrd3702","volume":"11","author":"G Griebel","year":"2012","unstructured":"Griebel, G. & Holsboer, F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat. Rev. Drug. Discov. 11, 462\u2013478 (2012).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"74990_CR12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/S0165-6147(99)01357-7","volume":"20","author":"J-P Vincent","year":"1999","unstructured":"Vincent, J.-P. et al. Neurotensin and neurotensin receptors. Trends Pharmacol. Sci. 20, 302\u2013309 (1999).","journal-title":"Trends Pharmacol. Sci."},{"key":"74990_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2017.03.046","volume":"805","author":"\u00c9 Besserer-Offroy","year":"2017","unstructured":"Besserer-Offroy, \u00c9 et al. The signaling signature of the neurotensin type 1 receptor with endogenous ligands. Eur. J. Pharmacol. 805, 1\u201313 (2017).","journal-title":"Eur. J. Pharmacol."},{"key":"74990_CR14","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/j.peptides.2006.04.025","volume":"27","author":"PR Dobner","year":"2006","unstructured":"Dobner, P. R. Neurotensin and pain modulation. Peptides 27, 2405\u20132414 (2006).","journal-title":"Peptides"},{"key":"74990_CR15","doi-asserted-by":"publisher","first-page":"840","DOI":"10.2174\/1381612820666141027124915","volume":"21","author":"Y-P Feng","year":"2015","unstructured":"Feng, Y.-P., Wang, J., Dong, Y.-L., Wang, Y.-Y. & Li, Y.-Q. The roles of neurotensin and its analogues in pain. Curr. Pharm. Des. 21, 840\u2013848 (2015).","journal-title":"Curr. Pharm. Des."},{"key":"74990_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jpain.2005.08.001","volume":"7","author":"LF Chu","year":"2006","unstructured":"Chu, L. F., Clark, D. J. & Angst, M. S. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J. Pain 7, 43\u201348 (2006).","journal-title":"J. Pain"},{"key":"74990_CR17","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","volume":"11","author":"R Benyamin","year":"2008","unstructured":"Benyamin, R. et al. Opioid complications and side effects. Pain Physician 11, S105\u2013S120 (2008).","journal-title":"Pain Physician"},{"key":"74990_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3390\/brainsci10080485","volume":"10","author":"K Lutfy","year":"2020","unstructured":"Lutfy, K. Opioid crisis\u2014an emphasis on fentanyl analogs. Brain Sci. 10, 485 (2020).","journal-title":"Brain Sci"},{"key":"74990_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1073\/pnas.90.1.65","volume":"90","author":"D Gully","year":"1993","unstructured":"Gully, D. et al. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc. Natl. Acad. Sci. 90, 65\u201369 (1993).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"74990_CR20","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/S0022-3565(24)36482-1","volume":"280","author":"D Gully","year":"1997","unstructured":"Gully, D. et al. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J. Pharmacol. Exp. Ther. 280, 802\u2013812 (1997).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"74990_CR21","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1021\/acschembio.5b00965","volume":"11","author":"RC Kling","year":"2016","unstructured":"Kling, R. C. et al. Development of covalent ligand\u2013receptor pairs to study the binding properties of nonpeptidic neurotensin receptor 1 antagonists. ACS Chem. Biol. 11, 869\u2013875 (2016).","journal-title":"ACS Chem. Biol."},{"key":"74990_CR22","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.bmcl.2009.01.024","volume":"19","author":"JB Thomas","year":"2009","unstructured":"Thomas, J. B., Navarro, H., Warner, K. R. & Gilmour, B. The identification of nonpeptide neurotensin receptor partial agonists from the potent antagonist SR48692 using a calcium mobilization assay. Bioorg. Med. Chem. Lett. 19, 1438\u20131441 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"74990_CR23","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1016\/j.bmcl.2014.06.033","volume":"24","author":"PD Fruscia","year":"2014","unstructured":"Fruscia, P. D. et al. The Discovery of Indole Full Agonists of the Neurotensin Receptor 1 (NTSR1). Bioorg. Med. Chem. Lett. 24, 3974 (2014).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"74990_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abe5504","volume":"7","author":"M Deluigi","year":"2021","unstructured":"Deluigi, M. et al. Complexes of the neurotensin receptor 1 with small-molecule ligands reveal structural determinants of full, partial, and inverse agonism. Sci. Adv. 7, eabe5504 (2021).","journal-title":"Sci. Adv."},{"key":"74990_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1124\/mol.117.111062","volume":"93","author":"K Sriram","year":"2018","unstructured":"Sriram, K. & Insel, P. A. G Protein-coupled receptors as targets for approved drugs: how many targets and how many drugs? Mol. Pharmacol. 93, 251\u2013258 (2018).","journal-title":"Mol. Pharmacol."},{"key":"74990_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8895","volume":"6","author":"BE Krumm","year":"2015","unstructured":"Krumm, B. E., White, J. F., Shah, P. & Grisshammer, R. Structural prerequisites for G-protein activation by the neurotensin receptor. Nat. Commun. 6, 7895 (2015).","journal-title":"Nat. Commun."},{"key":"74990_CR27","doi-asserted-by":"publisher","first-page":"E655","DOI":"10.1073\/pnas.1317903111","volume":"111","author":"P Egloff","year":"2014","unstructured":"Egloff, P. et al. Structure of signaling-competent neurotensin receptor 1 obtained by directed evolution in Escherichia coli. Proc. Natl. Acad. Sci. 111, E655\u2013E662 (2014).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"74990_CR28","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1021\/acs.biochem.3c00029","volume":"62","author":"BE Krumm","year":"2023","unstructured":"Krumm, B. E. et al. Neurotensin receptor allosterism revealed in complex with a biased allosteric modulator. Biochemistry 62, 1233\u20131248 (2023).","journal-title":"Biochemistry"},{"key":"74990_CR29","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41594-020-00554-6","volume":"28","author":"M Zhang","year":"2021","unstructured":"Zhang, M. et al. Cryo-EM structure of an activated GPCR\u2013G protein complex in lipid nanodiscs. Nat. Struct. Mol. Biol. 28, 258\u2013267 (2021).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"74990_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41586-019-1337-6","volume":"572","author":"HE Kato","year":"2019","unstructured":"Kato, H. E. et al. Conformational transitions of a neurotensin receptor 1\u2013Gi1 complex. Nature 572, 80\u201385 (2019).","journal-title":"Nature"},{"key":"74990_CR31","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-023-06395-9","volume":"620","author":"J Duan","year":"2023","unstructured":"Duan, J. et al. GPCR activation and GRK2 assembly by a biased intracellular agonist. Nature 620, 676\u2013681 (2023).","journal-title":"Nature"},{"key":"74990_CR32","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41422-019-0256-2","volume":"29","author":"W Yin","year":"2019","unstructured":"Yin, W. et al. A complex structure of arrestin-2 bound to a G protein-coupled receptor. Cell Res. 29, 971\u2013983 (2019).","journal-title":"Cell Res."},{"key":"74990_CR33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41586-020-1953-1","volume":"579","author":"W Huang","year":"2020","unstructured":"Huang, W. et al. Structure of the neurotensin receptor 1 in complex with \u03b2-arrestin 1. Nature 579, 303\u2013308 (2020).","journal-title":"Nature"},{"key":"74990_CR34","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nature11558","volume":"490","author":"JF White","year":"2012","unstructured":"White, J. F. et al. Structure of the agonist-bound neurotensin receptor. Nature 490, 508\u2013513 (2012).","journal-title":"Nature"},{"key":"74990_CR35","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S1043-9471(05)80049-7","volume":"25","author":"JA Ballesteros","year":"1995","unstructured":"Ballesteros, J. A. & Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci. 25, 366\u2013428 (1995).","journal-title":"Methods Neurosci."},{"key":"74990_CR36","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","volume":"55","author":"T Sterling","year":"2015","unstructured":"Sterling, T. & Irwin, J. J. ZINC 15 \u2013 ligand discovery for everyone. J. Chem. Inf. Model. 55, 2324\u20132337 (2015).","journal-title":"J. Chem. Inf. Model."},{"key":"74990_CR37","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1038\/s41596-021-00597-z","volume":"16","author":"BJ Bender","year":"2021","unstructured":"Bender, B. J. et al. A practical guide to large-scale docking. Nat. Protoc. 16, 4799\u20134832 (2021).","journal-title":"Nat. Protoc."},{"key":"74990_CR38","doi-asserted-by":"publisher","first-page":"e75992","DOI":"10.1371\/journal.pone.0075992","volume":"8","author":"RG Coleman","year":"2013","unstructured":"Coleman, R. G., Carchia, M., Sterling, T., Irwin, J. J. & Shoichet, B. K. Ligand pose and orientational sampling in molecular docking. PLoS One 8, e75992 (2013).","journal-title":"PLoS One"},{"key":"74990_CR39","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1021\/acs.jmedchem.0c02227","volume":"64","author":"A Fischer","year":"2021","unstructured":"Fischer, A., Smie\u0161ko, M., Sellner, M. & Lill, M. A. Decision making in structure-based drug discovery: visual inspection of docking results. J. Med. Chem. 64, 2489\u20132500 (2021).","journal-title":"J. Med. Chem."},{"key":"74990_CR40","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1021\/acs.jmedchem.0c01726","volume":"64","author":"M Chartier","year":"2021","unstructured":"Chartier, M. et al. Design, structural optimization, and characterization of the first selective macrocyclic neurotensin receptor type 2 non-opioid analgesic. J. Med. Chem. 64, 2110\u20132124 (2021).","journal-title":"J. Med. Chem."},{"key":"74990_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","volume":"23","author":"CA Lipinski","year":"1997","unstructured":"Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3\u201325 (1997).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"74990_CR42","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1146\/annurev-biochem-060614-033910","volume":"87","author":"WI Weis","year":"2018","unstructured":"Weis, W. I. & Kobilka, B. K. The molecular basis of G protein-coupled receptor activation. Annu. Rev. Biochem. 87, 897\u2013919 (2018).","journal-title":"Annu. Rev. Biochem."},{"key":"74990_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-021-02574-4","volume":"4","author":"J Budzinski","year":"2021","unstructured":"Budzinski, J. et al. Bivalent ligands promote endosomal trafficking of the dopamine D3 receptor-neurotensin receptor 1 heterodimer. Commun. Biol. 4, 1\u201313 (2021).","journal-title":"Commun. Biol."},{"key":"74990_CR44","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s42003-024-06490-1","volume":"7","author":"ESF Matthees","year":"2024","unstructured":"Matthees, E. S. F. et al. GRK specificity and G\u03b2\u03b3 dependency determines the potential of a GPCR for arrestin-biased agonism. Commun. Biol. 7, 802 (2024).","journal-title":"Commun. Biol."},{"key":"74990_CR45","doi-asserted-by":"publisher","first-page":"8357","DOI":"10.1021\/acs.jmedchem.9b00340","volume":"62","author":"AB Pinkerton","year":"2019","unstructured":"Pinkerton, A. B. et al. Discovery of \u03b2-arrestin biased, orally bioavailable, and CNS penetrant neurotensin receptor 1 (NTR1) allosteric modulators. J. Med. Chem. 62, 8357\u20138363 (2019).","journal-title":"J. Med. Chem."},{"key":"74990_CR46","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1124\/mol.114.094342","volume":"86","author":"A Christopoulos","year":"2014","unstructured":"Christopoulos, A. Advances in G protein-coupled receptor allostery: from function to structure. Mol. Pharmacol. 86, 463\u2013478 (2014).","journal-title":"Mol. Pharmacol."},{"key":"74990_CR47","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1021\/acsptsci.4c00086","volume":"7","author":"H Vogt","year":"2024","unstructured":"Vogt, H. et al. Development of a fluorescent ligand for the intracellular allosteric binding site of the neurotensin receptor 1. ACS Pharmacol. Transl. Sci. 7, 1533\u20131545 (2024).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"74990_CR48","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1016\/j.bbamem.2014.07.015","volume":"1838","author":"DJ Scott","year":"2014","unstructured":"Scott, D. J., Kummer, L., Egloff, P., Bathgate, R. A. D. & Pl\u00fcckthun, A. Improving the apo-state detergent stability of NTS1 with CHESS for pharmacological and structural studies. Biochim. Biophys. Acta 1838, 2817\u20132824 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"74990_CR49","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1110\/ps.033910.107","volume":"17","author":"YN Imai","year":"2008","unstructured":"Imai, Y. N., Inoue, Y., Nakanishi, I. & Kitaura, K. Cl\u2013\u03c0 interactions in protein\u2013ligand complexes. Protein Sci.\u00a017, 1129\u20131137 (2008).","journal-title":"Protein Sci"},{"key":"74990_CR50","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1021\/acs.jmedchem.5b01495","volume":"59","author":"M Keller","year":"2016","unstructured":"Keller, M. et al. Mimicking of arginine by functionalized n\u03c9-carbamoylated arginine as a new broadly applicable approach to labeled bioactive peptides: high affinity angiotensin, neuropeptide Y, neuropeptide FF, and neurotensin receptor ligands as examples. J. Med. Chem. 59, 1925\u20131945 (2016).","journal-title":"J. Med. Chem."},{"key":"74990_CR51","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/cmdc.201200376","volume":"8","author":"C Held","year":"2013","unstructured":"Held, C. et al. Development of a Metabolically Stable Neurotensin Receptor 2 (NTS2) Ligand. ChemMedChem 8, 75\u201381 (2013).","journal-title":"ChemMedChem"},{"key":"74990_CR52","doi-asserted-by":"crossref","unstructured":"Shiva, N. et al. Neurotensin receptor 2 agonism attenuates adverse cardiac remodeling in preclinical models. Sci. Transl. Med. 18, eaea9877 (2026).","DOI":"10.1126\/scitranslmed.aea9877"},{"key":"74990_CR53","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ejphar.2015.05.025","volume":"762","author":"OE Osadchii","year":"2015","unstructured":"Osadchii, O. E. Emerging role of neurotensin in regulation of the cardiovascular system. Eur. J. Pharmacol. 762, 184\u2013192 (2015).","journal-title":"Eur. J. Pharmacol."},{"key":"74990_CR54","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.peptides.2005.12.016","volume":"27","author":"D Zhao","year":"2006","unstructured":"Zhao, D. & Pothoulakis, C. Effects of NT on gastrointestinal motility and secretion, and role in intestinal inflammation. Peptides 27, 2434\u20132444 (2006).","journal-title":"Peptides"},{"key":"74990_CR55","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.pbb.2004.12.005","volume":"80","author":"WE Fantegrossi","year":"2005","unstructured":"Fantegrossi, W. E., Ko, M. C. H., Woods, J. H. & Richelson, E. Antinociceptive, hypothermic, hypotensive, and reinforcing effects of a novel neurotensin receptor agonist, NT69L, in rhesus monkeys. Pharmacol. Biochem. Behav. 80, 341\u2013349 (2005).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"74990_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202405941","volume":"63","author":"M Desgagn\u00e9","year":"2024","unstructured":"Desgagn\u00e9, M. et al. Development of macrocyclic neurotensin receptor Type\u20092 (NTS2) opioid-free analgesics. Angew. Chem., Int. Ed. 63, e202405941 (2024).","journal-title":"Angew. Chem., Int. Ed."},{"key":"74990_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/psc.3471","volume":"29","author":"S Previti","year":"2023","unstructured":"Previti, S. et al. Opening the amino acid toolbox for peptide-based NTS2-selective ligands as promising lead compounds for pain management. J. Pept. Sci. 29, e3471 (2023).","journal-title":"J. Pept. Sci."},{"key":"74990_CR58","doi-asserted-by":"publisher","first-page":"111861","DOI":"10.1016\/j.biopha.2021.111861","volume":"141","author":"M Chartier","year":"2021","unstructured":"Chartier, M. et al. Pharmacodynamic and pharmacokinetic profiles of a neurotensin receptor type 2 (NTS2) analgesic macrocyclic analog. Biomed. Pharmacother. 141, 111861 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"74990_CR59","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/0304-3959(92)90003-T","volume":"51","author":"A Tj\u00f8lsen","year":"1992","unstructured":"Tj\u00f8lsen, A., Berge, O.-G., Hunskaar, S., Rosland, J. H. & Hole, K. The formalin test: an evaluation of the method. Pain 51, 5\u201317 (1992).","journal-title":"Pain"},{"key":"74990_CR60","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0014-2999(97)01510-0","volume":"343","author":"C Betancur","year":"1998","unstructured":"Betancur, C. et al. Characterization of binding sites of a new neurotensin receptor antagonist, [3H]SR 142948A, in the rat brain. Eur. J. Pharmacol. 343, 67\u201377 (1998).","journal-title":"Eur. J. Pharmacol."},{"key":"74990_CR61","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1021\/acschemneuro.6b00097","volume":"7","author":"JB Thomas","year":"2016","unstructured":"Thomas, J. B. et al. Identification of 2-({[1-(4-fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)tricyclo[3.3.1.13,7]decane-2-carboxylic acid (NTRC-844) as a selective antagonist for the rat neurotensin receptor type 2. ACS Chem. Neurosci. 7, 1225\u20131231 (2016).","journal-title":"ACS Chem. Neurosci."},{"key":"74990_CR62","doi-asserted-by":"publisher","first-page":"8188","DOI":"10.1523\/JNEUROSCI.0810-05.2005","volume":"25","author":"P Sarret","year":"2005","unstructured":"Sarret, P. et al. Potent spinal analgesia elicited through stimulation of NTS2 neurotensin receptors. J. Neurosci. 25, 8188\u20138196 (2005).","journal-title":"J. Neurosci."},{"key":"74990_CR63","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1097\/j.pain.0000000000002561","volume":"163","author":"L Martin","year":"2022","unstructured":"Martin, L. et al. Conotoxin contulakin-G engages a neurotensin receptor 2\/R-type calcium channel (Cav2.3) pathway to mediate spinal antinociception. Pain 163, 1751\u20131762 (2022).","journal-title":"Pain"},{"key":"74990_CR64","doi-asserted-by":"publisher","first-page":"D1180","DOI":"10.1093\/nar\/gkad1004","volume":"52","author":"B Zdrazil","year":"2024","unstructured":"Zdrazil, B. et al. The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res. 52, D1180\u2013D1192 (2024).","journal-title":"Nucleic Acids Res."},{"key":"74990_CR65","doi-asserted-by":"publisher","first-page":"4956","DOI":"10.1016\/j.cell.2023.09.020","volume":"186","author":"MK Yadav","year":"2023","unstructured":"Yadav, M. K. et al. Molecular basis of anaphylatoxin binding, activation, and signaling bias at complement receptors. Cell 186, 4956\u20134973.e21 (2023).","journal-title":"Cell"},{"key":"74990_CR66","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.str.2019.12.003","volume":"28","author":"H Asada","year":"2020","unstructured":"Asada, H. et al. The crystal structure of angiotensin II type 2 receptor with endogenous peptide hormone. Structure 28, 418\u2013425.e4 (2020).","journal-title":"Structure"},{"key":"74990_CR67","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.cell.2022.12.026","volume":"186","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Structures of the entire human opioid receptor family. Cell 186, 413\u2013427.e17 (2023).","journal-title":"Cell"},{"key":"74990_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-27975-9","volume":"13","author":"J Qin","year":"2022","unstructured":"Qin, J. et al. Molecular mechanism of agonism and inverse agonism in ghrelin receptor. Nat. Commun. 13, 300 (2022).","journal-title":"Nat. Commun."},{"key":"74990_CR69","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1021\/ml400176n","volume":"4","author":"S Peddibhotla","year":"2013","unstructured":"Peddibhotla, S. et al. Discovery of ML314, a brain penetrant nonpeptidic \u03b2-arrestin biased agonist of the neurotensin NTR1 receptor. ACS Med. Chem. Lett. 4, 846\u2013851 (2013).","journal-title":"ACS Med. Chem. Lett."},{"key":"74990_CR70","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/s41586-022-05258-z","volume":"610","author":"AL Kaplan","year":"2022","unstructured":"Kaplan, A. L. et al. Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity. Nature 610, 582\u2013591 (2022).","journal-title":"Nature"},{"key":"74990_CR71","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1021\/acschembio.3c00602","volume":"19","author":"K Grotsch","year":"2024","unstructured":"Grotsch, K. et al. Virtual screening of a chemically diverse \u201csuperscaffold\u201d library enables ligand discovery for a key GPCR target. ACS Chem. Biol. 19, 866\u2013874 (2024).","journal-title":"ACS Chem. Biol."},{"key":"74990_CR72","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s44386-025-00031-4","volume":"2","author":"JH Lam","year":"2025","unstructured":"Lam, J. H. & Katritch, V. Navigating structure-based drug discovery with emerging innovations in physics- and knowledge-based approaches. npj Drug Discov. 2, 29 (2025).","journal-title":"npj Drug Discov."},{"key":"74990_CR73","doi-asserted-by":"publisher","first-page":"102829","DOI":"10.1016\/j.sbi.2024.102829","volume":"87","author":"J Carlsson","year":"2024","unstructured":"Carlsson, J. & Luttens, A. Structure-based virtual screening of vast chemical space as a starting point for drug discovery. Curr. Opin. Struct. Biol. 87, 102829 (2024).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"74990_CR74","doi-asserted-by":"publisher","first-page":"7437","DOI":"10.1021\/acs.jctc.3c00365","volume":"19","author":"M Papadourakis","year":"2023","unstructured":"Papadourakis, M. et al. Alchemical free energy calculations on membrane-associated proteins. J. Chem. Theory Comput. 19, 7437\u20137458 (2023).","journal-title":"J. Chem. Theory Comput."},{"key":"74990_CR75","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","volume":"31","author":"K Zhang","year":"2025","unstructured":"Zhang, K. et al. Artificial intelligence in drug development. Nat. Med. 31, 45\u201359 (2025).","journal-title":"Nat. Med."},{"key":"74990_CR76","doi-asserted-by":"publisher","first-page":"7817","DOI":"10.1021\/acs.jcim.5c00850","volume":"65","author":"L Shub","year":"2025","unstructured":"Shub, L. et al. Autoparty: machine learning-guided visual inspection of molecular docking results. J. Chem. Inf. Model. 65, 7817\u20137826 (2025).","journal-title":"J. Chem. Inf. Model."},{"key":"74990_CR77","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1126\/science.aau5595","volume":"364","author":"T Warne","year":"2019","unstructured":"Warne, T., Edwards, P. C., Dor\u00e9, A. S., Leslie, A. G. W. & Tate, C. G. Molecular basis for high-affinity agonist binding in GPCRs. Science 364, 775\u2013778 (2019).","journal-title":"Science"},{"key":"74990_CR78","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202218959","volume":"62","author":"N Panel","year":"2023","unstructured":"Panel, N. et al. Design of drug efficacy guided by free energy simulations of the \u03b22-adrenoceptor. Angew. Chem., Int. Ed. 62, e202218959 (2023).","journal-title":"Angew. Chem., Int. Ed."},{"key":"74990_CR79","first-page":"1","volume":"9","author":"M Zhang","year":"2024","unstructured":"Zhang, M. et al. G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery. Signal Transduct. Target. Ther. 9, 1\u201343 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"74990_CR80","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1124\/mol.60.6.1392","volume":"60","author":"F Richard","year":"2001","unstructured":"Richard, F., Barroso, S., Martinez, J., Labb\u00e9-Julli\u00e9, C. & Kitabgi, P. Agonism, inverse agonism, and neutral antagonism at the constitutively active human neurotensin receptor 2. Mol. Pharmacol. 60, 1392\u20131398 (2001).","journal-title":"Mol. Pharmacol."},{"key":"74990_CR81","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nrd.2017.229","volume":"17","author":"JS Smith","year":"2018","unstructured":"Smith, J. S., Lefkowitz, R. J. & Rajagopal, S. Biased signalling: from simple switches to allosteric microprocessors. Nat. Rev. Drug Discov. 17, 243\u2013260 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"74990_CR82","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.1016\/j.cell.2025.04.038","volume":"188","author":"R Guo","year":"2025","unstructured":"Guo, R. et al. Arrestin-biased allosteric modulator of neurotensin receptor 1 alleviates acute and chronic pain. Cell 188, 4332\u20134349.e21 (2025).","journal-title":"Cell"},{"key":"74990_CR83","unstructured":"OpenEye Scientific Software, Santa Fe, NM. https:\/\/www.eyesopen.com."},{"key":"74990_CR84","unstructured":"Landrum, G. et al. rdkit\/rdkit: 2019_09_3 (Q3 2019) Release. Zenodo 10.5281\/zenodo.3603542 (2020)."},{"key":"74990_CR85","unstructured":"ChemAxon. https:\/\/www.chemaxon.com."},{"key":"74990_CR86","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1021\/ci100031x","volume":"50","author":"PCD Hawkins","year":"2010","unstructured":"Hawkins, P. C. D., Skillman, A. G., Warren, G. L., Ellingson, B. A. & Stahl, M. T. Conformer generation with OMEGA: algorithm and validation using high quality structures from the protein databank and Cambridge Structural Database. J. Chem. Inf. Model. 50, 572\u2013584 (2010).","journal-title":"J. Chem. Inf. Model."},{"key":"74990_CR87","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1006\/jmbi.1998.2401","volume":"285","author":"JM Word","year":"1999","unstructured":"Word, J. M., Lovell, S. C., Richardson, J. S. & Richardson, D. C. Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. J. Mol. Biol. 285, 1735\u20131747 (1999).","journal-title":"J. Mol. Biol."},{"key":"74990_CR88","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/bip.360360210","volume":"36","author":"KA Sharp","year":"1995","unstructured":"Sharp, K. A. Polyelectrolyte electrostatics: Salt dependence, entropic, and enthalpic contributions to free energy in the nonlinear Poisson\u2013Boltzmann model. Biopolymers 36, 227\u2013243 (1995).","journal-title":"Biopolymers"},{"key":"74990_CR89","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0006-3495(98)77566-6","volume":"75","author":"K Gallagher","year":"1998","unstructured":"Gallagher, K. & Sharp, K. Electrostatic contributions to heat capacity changes of DNA-ligand binding. Biophys. J. 75, 769\u2013776 (1998).","journal-title":"Biophys. J."},{"key":"74990_CR90","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1021\/jm300687e","volume":"55","author":"MM Mysinger","year":"2012","unstructured":"Mysinger, M. M., Carchia, M., Irwin John, J. & Shoichet, B. K. Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J. Med. Chem. 55, 6582\u20136594 (2012).","journal-title":"J. Med. Chem."},{"key":"74990_CR91","unstructured":"Enamine REAL Space. https:\/\/enamine.net\/compound-collections\/real-compounds."},{"key":"74990_CR92","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13321-022-00606-7","volume":"14","author":"D Dolciami","year":"2022","unstructured":"Dolciami, D. et al. canSAR chemistry registration and standardization pipeline. J. Cheminform. 14, 28 (2022).","journal-title":"J. Cheminform."},{"key":"74990_CR93","doi-asserted-by":"crossref","unstructured":"Berthold, M. R. et al. KNIME: The Konstanz Information miner. In Studies in Classification, Data Analysis, and Knowledge Organization 319\u2013326 (Springer, 2008).","DOI":"10.1007\/978-3-540-78246-9_38"},{"key":"74990_CR94","doi-asserted-by":"publisher","first-page":"12046","DOI":"10.1073\/pnas.1813988115","volume":"115","author":"H Liu","year":"2018","unstructured":"Liu, H. et al. Structure-guided development of selective M3 muscarinic acetylcholine receptor antagonists. Proc. Natl. Acad. Sci. 115, 12046\u201312050 (2018).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"74990_CR95","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nsmb1134","volume":"13","author":"C Gal\u00e9s","year":"2006","unstructured":"Gal\u00e9s, C. et al. Probing the activation-promoted structural rearrangements in preassembled receptor\u2013G protein complexes. Nat. Struct. Mol. Biol. 13, 778\u2013786 (2006).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"74990_CR96","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1021\/acs.jmedchem.6b01857","volume":"60","author":"D M\u00f6ller","year":"2017","unstructured":"M\u00f6ller, D. et al. Discovery of G protein-biased dopaminergics with a pyrazolo[1,5-a]pyridine substructure. J. Med. Chem. 60, 2908\u20132929 (2017).","journal-title":"J. Med. Chem."},{"key":"74990_CR97","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1021\/jm991098z","volume":"43","author":"H H\u00fcbner","year":"2000","unstructured":"H\u00fcbner, H., Haubmann, C., Utz, W. & Gmeiner, P. Conjugated enynes as nonaromatic catechol bioisosteres:\u2009 synthesis, binding experiments, and computational studies of novel dopamine receptor agonists recognizing preferentially the D3 subtype. J. Med. Chem. 43, 756\u2013762 (2000).","journal-title":"J. Med. Chem."},{"key":"74990_CR98","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","volume":"22","author":"Y Cheng","year":"1973","unstructured":"Cheng, Y. & Prusoff, W. H. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099\u20133108 (1973).","journal-title":"Biochem. Pharmacol."},{"key":"74990_CR99","doi-asserted-by":"publisher","first-page":"30355","DOI":"10.1074\/jbc.M110.114900","volume":"285","author":"C Klenk","year":"2010","unstructured":"Klenk, C. et al. Formation of a ternary complex among NHERF1, \u03b2-arrestin, and parathyroid hormone receptor. J. Biol. Chem. 285, 30355\u201330362 (2010).","journal-title":"J. Biol. Chem."},{"key":"74990_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11472-x","volume":"7","author":"Y Wu","year":"2017","unstructured":"Wu, Y. et al. Rigidly connected multispecific artificial binders with adjustable geometries. Sci. Rep. 7, 11217 (2017).","journal-title":"Sci. Rep."},{"key":"74990_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27911-3","volume":"13","author":"M Deluigi","year":"2022","unstructured":"Deluigi, M. et al. Crystal structure of the \u03b11B-adrenergic receptor reveals molecular determinants of selective ligand recognition. Nat. Commun. 13, 382 (2022).","journal-title":"Nat. Commun."},{"key":"74990_CR102","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.pep.2014.10.006","volume":"108","author":"P Egloff","year":"2015","unstructured":"Egloff, P., Deluigi, M., Heine, P., Balada, S. & Pl\u00fcckthun, A. A cleavable ligand column for the rapid isolation of large quantities of homogeneous and functional neurotensin receptor 1 variants from E. coli. Protein Expr. Purif. 108, 106\u2013114 (2015).","journal-title":"Protein Expr. Purif."},{"key":"74990_CR103","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1107\/S0907444911007773","volume":"67","author":"C Vonrhein","year":"2011","unstructured":"Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. D 67, 293\u2013302 (2011).","journal-title":"Acta Crystallogr. D"},{"key":"74990_CR104","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"WXDS Kabsch","year":"2010","unstructured":"Kabsch, W. X. D. S. Acta Crystallogr. D 66, 125\u2013132 (2010).","journal-title":"Acta Crystallogr. D"},{"key":"74990_CR105","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1107\/S0907444913000061","volume":"69","author":"PR Evans","year":"2013","unstructured":"Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? Acta Crystallogr. D 69, 1204\u20131214 (2013).","journal-title":"Acta Crystallogr. D"},{"key":"74990_CR106","unstructured":"Tickle, I. J. et al. STARANISO. Cambridge, United Kingdom: Global Phasing Ltd (2018)."},{"key":"74990_CR107","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Cryst. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Cryst."},{"key":"74990_CR108","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1107\/S0907444996012255","volume":"53","author":"GN Murshudov","year":"1997","unstructured":"Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D 53, 240\u2013255 (1997).","journal-title":"Acta Crystallogr. D"},{"key":"74990_CR109","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. D"},{"key":"74990_CR110","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1107\/S2059798318002425","volume":"74","author":"TI Croll","year":"2018","unstructured":"Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. D 74, 519\u2013530 (2018).","journal-title":"Acta Crystallogr. D"},{"key":"74990_CR111","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4792","volume":"32","author":"EC Meng","year":"2023","unstructured":"Meng, E. C. et al. UCSF ChimeraX: tools for structure building and analysis. Protein Sci. 32, e4792 (2023).","journal-title":"Protein Sci."},{"key":"74990_CR112","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/pro.3330","volume":"27","author":"CJ Williams","year":"2018","unstructured":"Williams, C. J. et al. MolProbity: more and better reference data for improved all-atom structure validation. Protein Sci. 27, 293\u2013315 (2018).","journal-title":"Protein Sci."},{"key":"74990_CR113","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr. D"},{"key":"74990_CR114","doi-asserted-by":"publisher","unstructured":"Pach, S. & Carlsson, J. AANCHOR library: Amino Acid N\/C-termini Hybrids Optimized for Receptors. Zenodo https:\/\/doi.org\/10.5281\/zenodo.15094801 (2025).","DOI":"10.5281\/zenodo.15094801"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74990-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74990-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74990-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:02:53Z","timestamp":1784721773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74990-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":114,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["74990"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-74990-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.C. is a founder of DareMe Drug Discovery Consulting. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6970"}}